China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half of 2023, recording revenues of USD 40 million and nearly USD 3 million in profits, marking the company’s first profitable half-year. This financial success is attributed to a licensing agreement focused on batoclimab (HBM9161) and HBM7008.
Key Updates and Clinical Milestones
Other significant updates for Harbour BioMed include:
- The Phase III clinical study for batoclimab in generalized myasthenia gravis (gMG) yielded positive data during the period, showcasing the drug’s potential in treating this condition.
- The CTLA-4 antibody porustobart (HBM4003) has demonstrated significant efficacy and safety in clinical studies for melanoma, neuroendocrine tumors, and hepatocellular carcinoma, among other indications.
- HBM1020, a monoclonal antibody (mAb) targeting B7H7 and HHLA2, was first dosed in a patient in June, following the initiation of clinical trials in the US in January.
- The MSLN-targeted antibody drug conjugate (ADC) HBM9033 received clinical trial approval in the US this month, expanding Harbour’s clinical development efforts.
Pipeline Development and Commercial Cooperation
Harbour BioMed is actively developing its in-house pipelines, including HBM7022, HBM7008, and HBM9378, based on regional and global commercial cooperation strategies. Nona Bio, a subsidiary, has over 30 products under development, with 20 initiatives launched during the first half of 2023. The company expects to achieve substantial innovative results in areas such as immunocyte adapters, G-protein coupled receptors, mRNA technology, and more.-Fineline Info & Tech
